Clinical Research Details
Title:
Temsirolimus for Relapsed/Refractory Hodgkins Lymphoma
Purpose:
The primary objective of this study is to estimate the overall response rate (complete or partial response and stable disease by the IWG criteria) to temsirolimus, evaluate the toxicity of temsirolimus in this patient population, estimate the time to progression and overall survival after treatment with temsirolimus
Study Number:
201170101508
Number of Patients:
30
Elgibility:
Research participants must be at least 18 years of age and have biopsy-proven relapsed or refractory lymphoma.Participants may not be pregnant or nursing.
Treatment:
All participants will be treated with the study drug, temsirolimus, which will be given intravenously once a week. Before each treatment, you will be examined and have blood work checked. CT scans will be done about two months after the first treatment to see if the treatment is working.
Principal Investigator:
Enrollment Phone:
(708) 327-3223